Company intelligence / Profile preview

scucpra

Burlington, Massachusetts, United Statesarsuri.ro ↗

Ownership: Private
Development stage: Commercial

Overview

scPharmaceuticals has developed and commercialized FUROSCIX® (furosemide injection), an on-body infusor for subcutaneous delivery of furosemide to treat congestion in heart failure patients. The product received FDA approval in 2022 and launched commercially in 2023. Ongoing clinical development includes expanding indications to chronic kidney disease and new device formats such as autoinjectors.

Therapeutic areas: CardiovascularNephrology
Modalities: Small moleculeDevice
Industry: Biotech

Partnerships

Oaktree Capital ManagementPerceptive Advisors

Beyond the preview

Go deeper on scucpra.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on scucpra.

Explore the full profile